{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12C+Mutations&page=2", "query": { "condition": "KRAS G12C Mutations", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+G12C+Mutations&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T13:58:11.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06244771", "title": "A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors With KRAS G12C Mutations", "Solid Tumor, Adult", "Unresectable Solid Tumor", "Metastatic Solid Tumor", "Non Small Cell Lung Cancer", "Colorectal Cancer", "KRAS G12C", "Pancreatic Cancer" ], "interventions": [ { "name": "FMC-376", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Frontier Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 403, "start_date": "2024-02-12", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 15, "location_summary": "La Jolla, California • Orange, California • San Francisco, California + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Dyer", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244771" }, { "nct_id": "NCT05198934", "title": "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Trifluridine and Tipiracil", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 160, "start_date": "2022-04-19", "completion_date": "2026-04-14", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Duarte, California • Orange, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05198934" }, { "nct_id": "NCT04699188", "title": "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12C Mutant Solid Tumors", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Colorectal", "Cancer of Lung", "Cancer of the Lung", "Lung Cancer", "Neoplasms, Lung", "Neoplasms, Pulmonary", "Pulmonary Cancer", "Pulmonary Neoplasms" ], "interventions": [ { "name": "JDQ443", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 344, "start_date": "2021-02-24", "completion_date": "2027-01-25", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04699188" }, { "nct_id": "NCT07286149", "title": "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Neoplasm Malignant" ], "interventions": [ { "name": "MK-1084", "type": "DRUG" }, { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Rescue Medications", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2026-04-30", "completion_date": "2032-04-13", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 4, "location_summary": "Clermont, Florida • Chicago, Illinois • Portland, Oregon", "locations": [ { "city": "Clermont", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07286149" }, { "nct_id": "NCT04165031", "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3499446", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-28", "completion_date": "2020-10-30", "has_results": true, "last_update_posted_date": "2021-11-24", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165031" }, { "nct_id": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "MK-1084", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Sacituzumab tirumotecan (sac-TMT)", "type": "BIOLOGICAL" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2025-12-19", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 3, "location_summary": "Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota", "locations": [ { "city": "Clermont", "state": "Florida" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07252739" }, { "nct_id": "NCT06412198", "title": "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "KRAS G12C Mutations" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Adagrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2024-08-28", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06412198" }, { "nct_id": "NCT05162443", "title": "Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplasm" ], "interventions": [ { "name": "adagrasib (MRTX849)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 11, "location_summary": "San Francisco, California • Santa Rosa, California • Hartford, Connecticut + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05162443" }, { "nct_id": "NCT06973564", "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "JAB-23E73", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-05-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 4, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973564" }, { "nct_id": "NCT05789082", "title": "A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Divarasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2023-06-20", "completion_date": "2032-01-29", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-27T13:58:11.024Z", "location_count": 16, "location_summary": "Duarte, California • Huntington Beach, California • Irvine, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05789082" } ] }